84 related articles for article (PubMed ID: 9263367)
1. A model of human aiming movements applied to Parkinson's disease.
Suri RE; Albani C; Glattfelder AH
Technol Health Care; 1997 Jul; 5(3):177-90. PubMed ID: 9263367
[TBL] [Abstract][Full Text] [Related]
2. A dynamic model of motor basal ganglia functions.
Suri RE; Albani C; Glattfelder AH
Biol Cybern; 1997 Jun; 76(6):451-8. PubMed ID: 9263432
[TBL] [Abstract][Full Text] [Related]
3. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
[TBL] [Abstract][Full Text] [Related]
4. Influence of basal ganglia on upper limb locomotor synergies. Evidence from deep brain stimulation and L-DOPA treatment in Parkinson's disease.
Crenna P; Carpinella I; Lopiano L; Marzegan A; Rabuffetti M; Rizzone M; Lanotte M; Ferrarin M
Brain; 2008 Dec; 131(Pt 12):3410-20. PubMed ID: 18952669
[TBL] [Abstract][Full Text] [Related]
5. Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease.
Vaillancourt DE; Prodoehl J; Verhagen Metman L; Bakay RA; Corcos DM
Brain; 2004 Mar; 127(Pt 3):491-504. PubMed ID: 14662520
[TBL] [Abstract][Full Text] [Related]
6. Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements.
Kelly VE; Bastian AJ
Mov Disord; 2005 Jun; 20(6):694-704. PubMed ID: 15719427
[TBL] [Abstract][Full Text] [Related]
7. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
[TBL] [Abstract][Full Text] [Related]
8. Surface electromyography shows increased mirroring in Parkinson's disease patients without overt mirror movements.
Cincotta M; Giovannelli F; Borgheresi A; Balestrieri F; Vanni P; Ragazzoni A; Zaccara G; Ziemann U
Mov Disord; 2006 Sep; 21(9):1461-5. PubMed ID: 16705686
[TBL] [Abstract][Full Text] [Related]
9. Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia.
Maschke M; Gomez CM; Tuite PJ; Konczak J
Brain; 2003 Oct; 126(Pt 10):2312-22. PubMed ID: 12821507
[TBL] [Abstract][Full Text] [Related]
10. Effects of disease progression and L-dopa therapy on the control of reaching-grasping in Parkinson's disease.
Negrotti A; Secchi C; Gentilucci M
Neuropsychologia; 2005; 43(3):450-9. PubMed ID: 15707620
[TBL] [Abstract][Full Text] [Related]
11. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
Palmer SJ; Eigenraam L; Hoque T; McCaig RG; Troiano A; McKeown MJ
Neuroscience; 2009 Jan; 158(2):693-704. PubMed ID: 18722512
[TBL] [Abstract][Full Text] [Related]
12. Movement-related modulation of neural activity in human basal ganglia and its L-DOPA dependency: recordings from deep brain stimulation electrodes in patients with Parkinson's disease.
Priori A; Foffani G; Pesenti A; Bianchi A; Chiesa V; Baselli G; Caputo E; Tamma F; Rampini P; Egidi M; Locatelli M; Barbieri S; Scarlato G
Neurol Sci; 2002 Sep; 23 Suppl 2():S101-2. PubMed ID: 12548363
[TBL] [Abstract][Full Text] [Related]
13. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
14. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
15. Effect of subthalamic nucleus deep brain stimulation on axial motor control and protective arm responses in Parkinson's disease.
Visser JE; Allum JH; Carpenter MG; Esselink RA; Limousin-Dowsey P; Honegger F; Borm GF; Bloem BR
Neuroscience; 2008 Dec; 157(4):798-812. PubMed ID: 18952153
[TBL] [Abstract][Full Text] [Related]
16. Opioids and motor complications in Parkinson's disease.
Samadi P; Bédard PJ; Rouillard C
Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
18. Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease.
Bastian AJ; Kelly VE; Perlmutter JS; Mink JW
Mov Disord; 2003 Sep; 18(9):1008-17. PubMed ID: 14502668
[TBL] [Abstract][Full Text] [Related]
19. [Computerized method for arm movement assessment in Parkinson's disease and cerebellar syndrome patients].
Dordević O; Popović MB; Kostić V
Srp Arh Celok Lek; 2005; 133(1-2):14-20. PubMed ID: 16053170
[TBL] [Abstract][Full Text] [Related]
20. Effect of medication in Parkinson's disease: a wavelet analysis of EMG signals.
Strambi SK; Rossi B; De Michele G; Sello S
Med Eng Phys; 2004 May; 26(4):279-90. PubMed ID: 15121053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
